Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics Indian Medical PG Practice Questions and MCQs

Question 451: A drug with high plasma protein binding property has which of the following properties?

A. Reduced renal clearance
B. Less drug interaction
C. Less tubular secretion
D. Lower volume of distribution (Correct Answer)

Explanation: ***Lower volume of distribution*** - Drugs with high plasma protein binding are largely confined to the **vascular compartment** as they bind to proteins (e.g., albumin, alpha-1-acid glycoprotein), making them less available to distribute into tissues. - This confinement within the plasma compartment results in a **smaller apparent volume of distribution**. *Less drug interaction* - High plasma protein binding actually increases the potential for **drug-drug interactions** through displacement. - If a second drug displaces the first from its binding sites, it can increase the **free fraction** and potentially lead to toxicity. *Reduced renal clearance* - While highly protein-bound drugs are generally not easily filtered by the glomeruli, their primary route of elimination is often through **hepatic metabolism** or **active tubular secretion**, rather than reduced renal elimination. - Many highly protein-bound drugs still undergo significant renal excretion via **active secretion**, if they are substrates for active transporters. *Less tubular secretion* - Plasma protein binding does not inherently reduce tubular secretion; in some cases, the drug-protein complex can dissociate rapidly at the secretory sites, allowing for efficient secretion of the **free drug**. - In fact, many drugs that undergo significant tubular secretion are also highly protein-bound, as protein binding helps **maintain a concentration gradient** for and delivery of the drug to the secretion transporters.

Question 452: Which fluoroquinolone has the maximum bioavailability?

A. Gatifloxacin
B. Ciprofloxacin
C. Moxifloxacin
D. Levofloxacin (Correct Answer)

Explanation: ***Levofloxacin*** - **Levofloxacin** exhibits high oral bioavailability, approximately 99%, meaning nearly all of the administered dose reaches systemic circulation [1]. - This high bioavailability allows for seamless transition from intravenous to oral administration without significant changes in drug exposure [1]. *Moxifloxacin* - **Moxifloxacin** has a high bioavailability of approximately 90%, which is slightly lower than levofloxacin's almost complete absorption [1]. - While excellent, it is not the absolute highest among fluoroquinolones. *Gatifloxacin* - **Gatifloxacin** has good oral bioavailability, around 96%, but it is still generally considered slightly less than that of levofloxacin [1]. - This difference, though small, makes levofloxacin the one with the highest overall bioavailability. *Ciprofloxacin* - **Ciprofloxacin** has the lowest oral bioavailability among the listed fluoroquinolones, ranging from 70% to 80% [1]. - Its absorption can be significantly impaired by co-administration with multivalent cations, leading to reduced systemic concentrations.

Question 453: When alcohol is consumed with aerated soft drinks -

A. Effect is enhanced
B. To reduce hangover risk
C. Absorption is faster, increasing intoxication risk (Correct Answer)
D. None of the options

Explanation: ***Absorption is faster, increasing intoxication risk*** - The carbonation in aerated soft drinks speeds up the absorption of alcohol into the bloodstream. - This **faster absorption** leads to a more rapid increase in blood alcohol concentration and can intensify the effects of alcohol, thereby increasing the risk of intoxication. *Effect is enhanced* - While the **effect** might seem to be enhanced due to quicker onset, this option doesn't fully explain the physiological mechanism. - The primary reason for the perceived enhancement is the **accelerated absorption**, not a direct potentiation of alcohol's action. *To reduce hangover risk* - Mixing alcohol with aerated drinks generally **does not reduce hangover risk**; in fact, the rapid absorption can sometimes worsen dehydration and lead to a more severe hangover. - Hangovers are primarily caused by dehydration, acetaldehyde buildup, and other congeners, which are not mitigated by carbonated mixers. *None of the options* - This option is incorrect because the statement about **faster absorption leading to increased intoxication risk** is a well-established physiological effect.

Question 454: Which statement best describes first-order kinetics in pharmacokinetics?

A. Absorption of the drug is independent of the serum concentration
B. Elimination of the drug is proportional to the serum concentration (Correct Answer)
C. Absorption of the drug is proportional to the serum concentration
D. Elimination of the drug is independent of the serum concentration

Explanation: ***Elimination of the drug is proportional to the serum concentration*** - In **first-order kinetics**, a **constant fraction** (or percentage) of the drug is eliminated per unit of time. - This means that as the **serum drug concentration** increases, the absolute amount of drug eliminated per unit time also increases proportionally. *Absorption of the drug is independent of the serum concentration* - Drug absorption is generally driven by factors like **concentration gradient**, surface area, and blood flow, and while it can be influenced by drug concentration, this statement does not define first-order kinetics of *elimination*. - This statement is not the primary characteristic distinguishing first-order from zero-order kinetics regarding drug disposition. *Elimination of the drug is independent of the serum concentration.* - This describes **zero-order kinetics**, where a **constant amount** of drug is eliminated per unit of time, regardless of the serum concentration. - In zero-order kinetics, the elimination rate becomes saturated, so the elimination process cannot keep up with higher drug concentrations. *Absorption of the drug is proportional to the serum concentration* - While drug absorption can be proportional to the concentration (especially through passive diffusion), first-order kinetics specifically refers to the **elimination phase** of pharmacokinetics. - The rate of absorption can be a complex process and is not the defining characteristic for distinguishing first-order from zero-order *elimination*.

Question 455: Which of the following is a characteristic of simvastatin?

A. Specific CYP3A4 substrate with high interaction potential
B. Derived from fungal metabolite (Correct Answer)
C. Prodrug requiring hepatic activation
D. Short half-life requiring evening dosing

Explanation: ***Derived from fungal metabolite*** - **Simvastatin** and lovastatin are **naturally-derived statins** obtained from **fungal metabolites** (*Aspergillus terreus*), distinguishing them from synthetic statins like atorvastatin, rosuvastatin, and pravastatin [2]. - This is the **most distinguishing characteristic** for classification purposes, as it represents the drug's origin and places it in a specific subclass of HMG-CoA reductase inhibitors. - The discovery of fungal-derived statins led to the development of the entire statin drug class. *Prodrug requiring hepatic activation* - While **simvastatin** is a **lactone prodrug** requiring hepatic hydrolysis to its active beta-hydroxy acid form, this is a pharmacokinetic property shared with lovastatin [1]. - This is a characteristic but not the most distinguishing feature for classification. *Specific CYP3A4 substrate with high interaction potential* - **Simvastatin** is extensively metabolized by **CYP3A4**, leading to significant drug-drug interactions with CYP3A4 inhibitors (e.g., ketoconazole, erythromycin, grapefruit juice). - While clinically important, many drugs are CYP3A4 substrates, making this less distinctive as a defining characteristic. *Short half-life requiring evening dosing* - **Simvastatin** has a **short half-life** (2-3 hours) and is preferably administered in the evening because cholesterol synthesis is highest at night. - This is a dosing consideration based on pharmacokinetics rather than a fundamental distinguishing characteristic of the drug's identity.

Question 456: High volume of distribution is primarily determined by:

A. High lipid solubility (Correct Answer)
B. High plasma protein binding
C. Elimination rate
D. Half-life of the drug

Explanation: ***High lipid solubility***- Highly **lipid-soluble** drugs readily cross biological membranes and distribute extensively into tissues, including adipose tissue, CNS, and intracellular compartments, leading to a **high volume of distribution (Vd)** [1, 2].- This property allows the drug to move out of the bloodstream and into various body compartments, increasing the apparent volume in which the drug is dissolved [1].*High plasma protein binding*- **High plasma protein binding** generally **restricts** drug distribution to tissues because only the **unbound (free) fraction** can diffuse across capillary membranes into interstitial fluid and cells [1].- This typically leads to a **lower Vd**, as the drug is largely retained within the plasma compartment.*Elimination rate*- The **elimination rate** determines how quickly the drug is removed from the body, affecting the **duration of action** rather than the extent of distribution.- It influences drug concentration changes over time but does not directly determine the physical space (volume) into which the drug distributes.*Half-life of the drug*- The **half-life (t½)** is the time required for drug concentration to reduce by half, and it is **determined by** both Vd and clearance (t½ = 0.693 × Vd/CL).- Half-life is a **consequence** of Vd and clearance, not a primary determinant of how widely a drug distributes [3].

Question 457: Where does the oxidation of drugs mainly take place?

A. Smooth ER (Correct Answer)
B. Rough ER
C. Cytoplasm
D. Nucleus

Explanation: **Smooth ER** - The **smooth endoplasmic reticulum (SER)** is rich in enzymes, particularly the **cytochrome P450 system**, which is primarily responsible for phase I **oxidation reactions** of many drugs and xenobiotics [1]. - These oxidative reactions typically **increase the polarity** of drugs, making them easier to excrete [1]. *Nucleus* - The nucleus primarily contains the cell's **genetic material** (DNA) and is involved in **gene expression** and replication. - It does not contain the necessary enzymatic machinery for the major oxidative metabolism of drugs. *Rough ER* - The **rough endoplasmic reticulum (RER)** is characterized by the presence of **ribosomes** and is mainly involved in the **synthesis, folding, modification, and transport of proteins** destined for secretion or insertion into membranes [2]. - While it plays a role in protein synthesis, it is not the primary site for drug oxidation. *Cytoplasm* - The cytoplasm contains various organelles and is the site of many metabolic pathways, including **glycolysis** and some **phase II drug metabolism** (e.g., glucuronidation, sulfation) [1]. - However, the bulk of phase I **oxidative drug metabolism** does not occur in the general cytoplasm but rather within the smooth ER due to the concentration of relevant enzymes there [1].

Question 458: Which drug is not administered as a transdermal patch?

A. Morphine (Correct Answer)
B. Fentanyl
C. Clonidine
D. Diclofenac

Explanation: ***Morphine*** - **Morphine** is generally not administered transdermally due to its **poor lipid solubility** [1] and **large molecular size**, which limit its ability to penetrate the skin effectively. - While experimental patches have been developed, they are **not widely available** or commonly used in clinical practice for systemic delivery. *Fentanyl* - **Fentanyl** is a potent opioid that is commonly administered via a **transdermal patch** for chronic pain management [2]. - Its **high lipid solubility** and small molecular size allow it to be effectively absorbed through the skin, providing sustained analgesia. *Clonidine* - **Clonidine** is an alpha-2 adrenergic agonist available as a **transdermal patch** for the treatment of **hypertension**. - The patch provides a **continuous and steady release** of the drug, leading to consistent blood pressure control. *Diclofenac* - **Diclofenac** is a non-steroidal anti-inflammatory drug (NSAID) available in **transdermal patch** formulations for topical pain relief. - These patches are used for localized pain conditions like **osteoarthritis** and provide targeted drug delivery with reduced systemic side effects.

Question 459: Maximum cycloplegic action of atropine is seen at ?

A. 1-3 hours (Correct Answer)
B. 1-2 weeks
C. 4-6 hours
D. 30-60 minutes

Explanation: ***1-3 hours*** - Atropine, a **non-selective muscarinic antagonist**, reaches its **peak cycloplegic effect** approximately 1 to 3 hours after topical administration. - This peak activity is crucial for accurate retinoscopy and **refractive error measurement** in children, as it effectively paralyzes the ciliary muscle. *4-6 hours* - While atropine's cycloplegic effect is still present at 4-6 hours, it is generally **past its peak action** by this time. - Slower-acting cycloplegics might have their peak around this window, but not atropine. *1-2 weeks* - The **duration of action** for atropine's cycloplegic and mydriatic effects can last for 1-2 weeks, but this is the total duration, not when the maximum action is observed. - Patients are often instructed about the **prolonged effects** and potential for blurred vision and photophobia over this period. *30-60 minutes* - While some mydriatic effects might start within 30-60 minutes, the **full cycloplegic effect** of atropine, which requires maximum paralysis of the ciliary muscle, is not achieved in this short timeframe. - Shorter-acting cycloplegics like **cyclopentolate** or **tropicamide** would show peak action within this earlier interval.

Question 460: Which of the following drug combinations demonstrates receptor level antagonism?

A. Histamine and Adrenaline
B. Isoprenaline (agonist) and Propranolol (antagonist) (Correct Answer)
C. Adrenaline and Isoprenaline
D. None of the options

Explanation: ***Isoprenaline (agonist) and Propranolol (antagonist)*** - **Propranolol** is a **beta-adrenergic receptor antagonist**, meaning it binds to and blocks beta-adrenergic receptors. - **Isoprenaline** is a **beta-adrenergic receptor agonist**, meaning it activates these same receptors. Their combined action demonstrates **receptor-level antagonism** as propranolol prevents isoprenaline from binding and eliciting its effect. *Histamine and Adrenaline* - This combination illustrates **physiological antagonism**, where two drugs produce opposite effects through different mechanisms and different receptors. - **Adrenaline** causes bronchodilation and vasoconstriction via adrenergic receptors, counteracting the effects of **histamine** (e.g., bronchoconstriction, vasodilation) which acts on histamine receptors. *Adrenaline and Isoprenaline* - Both **adrenaline** and **isoprenaline** are **agonists** of adrenergic receptors, specifically beta-adrenergic receptors. - They would produce similar effects (e.g., increased heart rate, bronchodilation) rather than opposing each other at the receptor level. *None of the options* - This is incorrect because **Isoprenaline and Propranolol** is a valid example of receptor-level antagonism, making this option unnecessary.

Practice by Chapter

Absorption and Bioavailability

Practice Questions

Drug Distribution and Protein Binding

Practice Questions

Biotransformation and Metabolism Pathways

Practice Questions

Renal and Non-renal Excretion

Practice Questions

Compartment Models

Practice Questions

Dose-Response Relationships

Practice Questions

Drug Efficacy and Potency

Practice Questions

Drug Tolerance and Tachyphylaxis

Practice Questions

Population Pharmacokinetics

Practice Questions

Pharmacokinetic Variability

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free